Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBL949 in obese adults with or without type 2 diabetes mellitus: randomized placebo-controlled phase 2 study
2021-004449-19Phase 2Terminated
- Sponsor
- Novartis
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing MBL949 active treatment with Placebo control (2 arms). Primary endpoint: Frequency and severity of adverse events. Started Feb 2022; status: terminated.
02
Drugs
MBL949
03
Conditions
obesity
Beyond the preview
Go deeper on 2021-004449-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004449-19.